A Study Evaluating Escalating Doses of 131I-BC8 (Anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies

Trial Profile

A Study Evaluating Escalating Doses of 131I-BC8 (Anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Jun 2016

At a glance

  • Drugs Anti-CD45 monoclonal antibody BC8 I-131 (Primary)
  • Indications B cell lymphoma; Hodgkin's disease; Mantle-cell lymphoma; T cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 19 May 2016 Status changed from recruiting to active, no longer recruiting.
    • 13 Oct 2015 Planned primary completion date changed from 1 Mar 2016 to 1 Sep 2016, as reported by ClinicalTrials.gov.
    • 15 Apr 2015 Planned primary completion date changed from 1 Mar 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top